Artrodar®50mg (diacerein): New restrictions of use to limit the risk of severe diarrhoea and effects on the liver

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

Date: 12 February 2015


A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the risk of severe diarrhoea and hepatotoxicity with the osteoarthritis medication, Artrodar® (diacerein). The use has been restricted to minimise these risks, including tightening of indication and recommending a lower starting dose.The package inserts for Artrodar® will be updated by TRB Chemedica Malaysia Sdn. reflect these safety changes. Please refer to the DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Monday 26 October 2020, 14:24:13.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language